40,419 XNAS Volume
XNAS 19 Mar, 2025 11:49 AM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Randall Michael Giuffre | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.11 per share. | 13 Feb 2025 | 12,000 | 387,412 (2%) | 0% | 2.1 | 25,320 | Voting Common Shares, no par value per share |
| Randall Michael Giuffre | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 5,000 | 0 | - | - | Stock Option (right to buy) | |
| Randall Michael Giuffre | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 12,000 | 0 | - | - | Stock Option (right to buy) | |
| Randall Michael Giuffre | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.65 per share. | 13 Feb 2025 | 5,000 | 392,412 (2%) | 0% | 3.7 | 18,250 | Voting Common Shares, no par value per share |
| Richard E. Kuntz | Director | Grant, award, or other acquisition of securities at price $ 5.34 per share. | 02 Jan 2025 | 9,925 | 24,210 (0%) | 0% | 5.3 | 53,000 | Voting Common Shares, no par value per share |
| James Parsons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 4,287 | 4,287 | - | - | Stock Option (right to buy) | |
| James Parsons | Director | Grant, award, or other acquisition of securities at price $ 5.34 per share. | 02 Jan 2025 | 15,917 | 75,854 (0%) | 0% | 5.3 | 84,997 | Voting Common Shares, no par value per share |
| Richard D. Pilnik | Director | Grant, award, or other acquisition of securities at price $ 5.34 per share. | 02 Jan 2025 | 10,393 | 288,995 (2%) | 0% | 5.3 | 55,499 | Voting Common Shares, no par value per share |
| Randall Michael Giuffre | Director | Grant, award, or other acquisition of securities at price $ 5.34 per share. | 02 Jan 2025 | 10,861 | 375,412 (2%) | 0% | 5.3 | 57,998 | Voting Common Shares, no par value per share |
| Charles Semba | Director | Grant, award, or other acquisition of securities at price $ 5.34 per share. | 02 Jan 2025 | 5,290 | 44,608 (0%) | 0% | 5.3 | 28,249 | Voting Common Shares, no par value per share |
| Richard E. Kuntz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2024 | 28,472 | 28,472 | - | - | Stock Option (right to buy) | |
| Tanya Lewis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2024 | 28,472 | 28,472 | - | - | Stock Option (right to buy) | |
| James Parsons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2024 | 28,472 | 28,472 | - | - | Stock Option (right to buy) | |
| Richard D. Pilnik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2024 | 36,065 | 36,065 | - | - | Stock Option (right to buy) | |
| Dietrich John Pauls | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2024 | 300,000 | 300,000 | - | - | Stock Option (right to buy) | |
| Charles Semba | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2024 | 28,472 | 28,472 | - | - | Stock Option (right to buy) | |
| Scott Kellen | CFO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2024 | 130,000 | 130,000 | - | - | Stock Option (right to buy) | |
| Dominic R. Cundari | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2024 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| David J. Wambeke | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2024 | 130,000 | 130,000 | - | - | Stock Option (right to buy) | |
| E. Kuntz Richard | Director | Grant, award, or other acquisition of securities at price $ 2.80 per share. | 02 Jan 2024 | 14,285 | 14,285 (0%) | 0% | 2.8 | 39,998 | Voting Common Shares, no par value per share |
| James Parsons | Director | Grant, award, or other acquisition of securities at price $ 2.80 per share. | 02 Jan 2024 | 21,428 | 59,937 (0%) | 0% | 2.8 | 59,998 | Voting Common Shares, no par value per share |
| D. Pilnik Richard | Director | Grant, award, or other acquisition of securities at price $ 2.80 per share. | 02 Jan 2024 | 30,357 | 278,602 (1%) | 0% | 2.8 | 85,000 | Voting Common Shares, no par value per share |
| Michael Randall Giuffre | Director | Grant, award, or other acquisition of securities at price $ 2.80 per share. | 02 Jan 2024 | 19,196 | 364,551 (2%) | 0% | 2.8 | 53,749 | Voting Common Shares, no par value per share |
| Charles Semba | Director | Grant, award, or other acquisition of securities at price $ 2.80 per share. | 02 Jan 2024 | 9,375 | 39,318 (0%) | 0% | 2.8 | 26,250 | Voting Common Shares, no par value per share |
| Richard D. Pilnik | Director | Purchase of securities on an exchange or from another person at price $ 3.91 per share. | 23 Jun 2023 | 38,363 | 248,245 (1%) | 0% | 3.9 | 149,999 | Voting Common Shares, no par value per share |
| Scott Kellen | CFO and Secretary | Purchase of securities on an exchange or from another person at price $ 3.91 per share. | 23 Jun 2023 | 10,000 | 32,290 (0%) | 0% | 3.9 | 39,100 | Voting Common Shares, no par value per share |
| Randall Michael Giuffre | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 23 Jun 2023 | 15,000 | 345,355 (2%) | 0% | 0 | Voting Common Shares, no par value per share | |
| Randall Michael Giuffre | Director | Purchase of securities on an exchange or from another person at price $ 3.91 per share. | 23 Jun 2023 | 65,000 | 360,355 (2%) | 0% | 3.9 | 254,150 | Voting Common Shares, no par value per share |
| Dietrich John Pauls | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 3.91 per share. | 23 Jun 2023 | 12,787 | 68,591 (0%) | 0% | 3.9 | 49,997 | Voting Common Shares, no par value per share |
| Charles Semba | Director | Purchase of securities on an exchange or from another person at price $ 3.91 per share. | 23 Jun 2023 | 12,787 | 29,943 (0%) | 0% | 3.9 | 49,997 | Voting Common Shares, no par value per share |
| David J. Wambeke | Chief Business Officer | Purchase of securities on an exchange or from another person at price $ 3.91 per share. | 23 Jun 2023 | 38,364 | 507,114 (3%) | 0% | 3.9 | 150,003 | Voting Common Shares, no par value per share |
| Tanya Lewis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 7,493 | 7,493 | - | - | Stock Option (right to buy) | |
| James Parsons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 16,968 | 16,968 | - | - | Stock Option (right to buy) | |
| Richard D. Pilnik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 22,355 | 22,355 | - | - | Stock Option (right to buy) | |
| Scott Kellen | CFO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 67,000 | 67,000 | - | - | Stock Option (right to buy) | |
| Randall Michael Giuffre | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 16,968 | 16,968 | - | - | Stock Option (right to buy) | |
| Dietrich John Pauls | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 181,000 | 181,000 | - | - | Stock option (right to buy) | |
| Charles Semba | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 16,968 | 16,968 | - | - | Stock Option (right to buy) | |
| Kirsten L. Gruis | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 67,000 | 67,000 | - | - | Stock Option (right to buy) | |
| Dominic R. Cundari | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 27,000 | 27,000 | - | - | Stock Option (right to buy) | |
| Julie VanOrsdel Daves | SVP Clinical Development Oper. | 01 Jun 2023 | 54,000 | 54,000 | - | - | Stock Option (right to buy) | ||
| Richard E. Kuntz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2023 | 32,320 | 32,320 | - | - | Stock option (right to buy) | |
| David J. Wambeke | Chief Business Officer | Purchase of securities on an exchange or from another person at price $ 1.60 per share. | 10 Apr 2023 | 468,750 | 468,750 (3%) | 3% | 1.6 | 750,000 | Voting Common Shares, no par value per share |
| David J. Wambeke | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Apr 2023 | 140,000 | 140,000 | - | - | Stock Option (right to buy) | |
| Tanya Lewis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 26,443 | 26,443 | - | - | Stock option (right to buy) | |
| Richard D. Pilnik | Director | Grant, award, or other acquisition of securities at price $ 1.53 per share. | 03 Jan 2023 | 55,555 | 209,882 (1%) | 0% | 1.5 | 84,999 | Voting Common Shares, no par value per share |
| Randall Michael Giuffre | Director | Grant, award, or other acquisition of securities at price $ 1.53 per share. | 03 Jan 2023 | 35,130 | 295,355 (2%) | 0% | 1.5 | 53,749 | Voting Common Shares, no par value per share |
| Charles Semba | Director | Grant, award, or other acquisition of securities at price $ 1.53 per share. | 03 Jan 2023 | 17,156 | 17,156 (0%) | 0% | 1.5 | 26,249 | Voting Common Shares, no par value per share |
| Amy Burroughs | Director | Grant, award, or other acquisition of securities at price $ 1.53 per share. | 03 Jan 2023 | 17,156 | 73,288 (0%) | 0% | 1.5 | 26,249 | Voting Common Shares, no par value per share |
| Randall Michael Giuffre | Director | Purchase of securities on an exchange or from another person at price $ 1.40 per share. | 08 Dec 2022 | 20,000 | 223,146 (1%) | 0% | 1.4 | 28,000 | Voting Common Shares, no par value per share |
| Randall Michael Giuffre | Director | Purchase of securities on an exchange or from another person at price $ 1.43 per share. | 08 Dec 2022 | 37,079 | 260,225 (1%) | 0% | 1.4 | 53,023 | Voting Common Shares, no par value per share |
| Randall Michael Giuffre | Director | Purchase of securities on an exchange or from another person at price $ 1.40 per share. | 06 Dec 2022 | 22,574 | 203,146 (1%) | 0% | 1.4 | 31,604 | Voting Common Shares, no par value per share |
| Randall Michael Giuffre | Director | Purchase of securities on an exchange or from another person at price $ 1.35 per share. | 06 Dec 2022 | 2,300 | 180,572 (1%) | 0% | 1.4 | 3,105 | Voting Common Shares, no par value per share |
| Richard D. Pilnik | Director | Purchase of securities on an exchange or from another person at price $ 1.39 per share. | 05 Dec 2022 | 35,000 | 154,327 (1%) | 0% | 1.4 | 48,493 | Voting Common Shares, no par value per share |
| Randall Michael Giuffre | Director | Purchase of securities on an exchange or from another person at price $ 1.19 per share. | 01 Dec 2022 | 819 | 178,272 (1%) | 0% | 1.2 | 975 | Voting Common Shares, no par value per share |
| Randall Michael Giuffre | Director | Purchase of securities on an exchange or from another person at price $ 1.19 per share. | 29 Nov 2022 | 2,970 | 131,320 (0%) | 0% | 1.2 | 3,534 | Voting Common Shares, no par value per share |
| Randall Michael Giuffre | Director | Purchase of securities on an exchange or from another person at price $ 1.19 per share. | 29 Nov 2022 | 18,125 | 128,350 (0%) | 0% | 1.2 | 21,569 | Voting Common Shares, no par value per share |
| Randall Michael Giuffre | Director | Purchase of securities on an exchange or from another person at price $ 1.20 per share. | 29 Nov 2022 | 46,133 | 177,453 (1%) | 0% | 1.2 | 55,360 | Voting Common Shares, no par value per share |
| Dietrich John Pauls | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 1.21 per share. | 16 Nov 2022 | 20,000 | 55,804 (0%) | 0% | 1.2 | 24,200 | Voting Common Shares, no par value per share |
| Julie VanOrsdel Daves | SVP Clinical Development Oper. | 13 Sep 2022 | 140,000 | 140,000 | - | - | Stock Option (right to buy) | ||
| James Parsons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 13,222 | 13,222 | - | - | Stock Option (right to buy) | |
| Richard D. Pilnik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 18,510 | 18,510 | - | - | Stock Option (right to buy) | |
| Scott Kellen | CFO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Randall Michael Giuffre | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 13,222 | 13,222 | - | - | Stock Option (right to buy) | |
| Dietrich John Pauls | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 177,000 | 177,000 | - | - | Stock Option (right to buy) | |
| Charles Semba | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 13,222 | 13,222 | - | - | Stock Option (right to buy) | |
| Amy Burroughs | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 13,222 | 13,222 | - | - | Stock Option (right to buy) | |
| Dominic R. Cundari | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 125,000 | 125,000 | - | - | Stock Option (right to buy) | |
| Dominic R. Cundari | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| James Parsons | Director | Grant, award, or other acquisition of securities at price $ 3.58 per share. | 03 Jan 2022 | 16,773 | 38,509 (0%) | 0% | 3.6 | 60,047 | Voting Common Shares, no par value per share |
| Richard D. Pilnik | Director | Grant, award, or other acquisition of securities at price $ 3.58 per share. | 03 Jan 2022 | 23,762 | 119,327 (0%) | 0% | 3.6 | 85,068 | Voting Common Shares, no par value per share |
| Randall Michael Giuffre | Director | Grant, award, or other acquisition of securities at price $ 3.58 per share. | 03 Jan 2022 | 15,026 | 110,225 (0%) | 0% | 3.6 | 53,793 | Voting Common Shares, no par value per share |
| Amy Burroughs | Director | Grant, award, or other acquisition of securities at price $ 3.58 per share. | 03 Jan 2022 | 11,182 | 56,132 (0%) | 0% | 3.6 | 40,032 | Voting Common Shares, no par value per share |
| Kirsten L. Gruis | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 160,000 | 160,000 | - | - | Stock Option (right to buy) | |
| Harry W. Alcorn | SVP, Clinical Operations | Purchase of securities on an exchange or from another person at price $ 3.80 per share. | 15 Sep 2021 | 15,000 | 43,582 (0%) | 0% | 3.8 | 56,960 | Voting Common Shares, no par value per share |
| Harry W. Alcorn | Senior VP, Clinical Operations | Purchase of securities on an exchange or from another person at price $ 3.06 per share. | 16 Aug 2021 | 322 | 28,582 (0%) | 0% | 3.1 | 985 | Voting Common Shares, no par value per share |
| Harry W. Alcorn | Senior VP, Clinical Operations | Purchase of securities on an exchange or from another person at price $ 3.09 per share. | 16 Aug 2021 | 20,000 | 28,260 (0%) | 0% | 3.1 | 61,844 | Voting Common Shares, no par value per share |
| Harry W. Alcorn | Senior VP, Clinical Operations | Purchase of securities on an exchange or from another person at price $ 3.07 per share. | 16 Aug 2021 | 399 | 399 (0%) | 0% | 3.1 | 1,225 | Voting Common Shares, no par value per share |
| Richard D. Pilnik | Director | Purchase of securities on an exchange or from another person at price $ 3.28 per share. | 16 Aug 2021 | 12,500 | 95,565 (0%) | 0% | 3.3 | 41,033 | Voting Common Shares, no par value per share |
| Richard D. Pilnik | Director | Purchase of securities on an exchange or from another person at price $ 3.21 per share. | 16 Aug 2021 | 2,500 | 83,065 (0%) | 0% | 3.2 | 8,032 | Voting Common Shares, no par value per share |
| Scott Kellen | CFO and Secretary | Purchase of securities on an exchange or from another person at price $ 3.15 per share. | 16 Aug 2021 | 10,000 | 22,290 (0%) | 0% | 3.1 | 31,463 | Voting Common Shares, no par value per share |
| Dietrich John Pauls | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 3.14 per share. | 16 Aug 2021 | 5,000 | 35,804 (0%) | 0% | 3.1 | 15,700 | Voting Common Shares, no par value per share |
| Amy Burroughs | Director | Purchase of securities on an exchange or from another person at price $ 3.15 per share. | 16 Aug 2021 | 44,950 | 44,950 (0%) | 0% | 3.2 | 141,593 | Voting Common Shares, no par value per share |
| Harry W. Alcorn | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2021 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Scott Kellen | CFO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2021 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Dietrich John Pauls | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2021 | 175,000 | 175,000 | - | - | Stock Option (right to buy) | |
| Sydney A. Gilman | VP, Regulatory Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2021 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| James Parsons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2021 | 9,393 | 9,393 | - | - | Stock Option (right to buy) | |
| Richard D. Pilnik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2021 | 13,150 | 13,150 | - | - | Stock Option (right to buy) | |
| Randall Michael Giuffre | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2021 | 9,393 | 9,393 | - | - | Stock Option (right to buy) | |
| Charles Semba | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2021 | 18,786 | 18,786 | - | - | Stock Option (right to buy) | |
| Amy Burroughs | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2021 | 18,786 | 18,786 | - | - | Stock Option (right to buy) | |
| James Parsons | Director | Grant, award, or other acquisition of securities at price $ 8.23 per share. | 01 Jan 2021 | 7,745 | 21,947 (0%) | 0% | 8.2 | 63,741 | Voting Common Shares, no par value per share |
| Richard D. Pilnik | Director | Grant, award, or other acquisition of securities at price $ 8.23 per share. | 01 Jan 2021 | 9,719 | 80,565 (0%) | 0% | 8.2 | 79,987 | Voting Common Shares, no par value per share |
| Randall Michael Giuffre | Director | Grant, award, or other acquisition of securities at price $ 8.23 per share. | 01 Jan 2021 | 7,441 | 116,029 (0%) | 0% | 8.2 | 61,239 | Voting Common Shares, no par value per share |
| Richard D. Pilnik | Director | Purchase of securities on an exchange or from another person at price $ 5.24 per share. | 04 Dec 2020 | 5,000 | 70,846 (0%) | 0% | 5.2 | 26,200 | Voting Common Shares, no par value per share |
| Richard D. Pilnik | Director | Purchase of securities on an exchange or from another person at price $ 5.50 per share. | 04 Dec 2020 | 5,000 | 65,846 (0%) | 0% | 5.5 | 27,497 | Voting Common Shares, no par value per share |
| Randall Michael Giuffre | Director | Purchase of securities on an exchange or from another person at price $ 4.26 per share. | 20 Nov 2020 | 15,000 | 108,588 (0%) | 0% | 4.3 | 63,912 | Voting Common Shares, no par value per share |
| Scott Kellen | CFO and Secretary | Purchase of securities on an exchange or from another person at price $ 4.19 per share. | 09 Nov 2020 | 2,000 | 12,290 (0%) | 0% | 4.2 | 8,387 | Voting Common Shares, no par value per share |
| Harry W. Alcorn | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2020 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| James Parsons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2020 | 13,306 | 13,306 | - | - | Stock Option (right to buy) | |
| James Parsons | Director | Grant, award, or other acquisition of securities at price $ 4.59 per share. | 01 Jun 2020 | 8,102 | 14,202 (0%) | 0% | 4.6 | 37,188 | Voting Common Shares, no par value per share |
| Richard D. Pilnik | Director | Grant, award, or other acquisition of securities at price $ 4.59 per share. | 01 Jun 2020 | 10,168 | 60,846 (0%) | 0% | 4.6 | 46,671 | Voting Common Shares, no par value per share |
| Richard D. Pilnik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2020 | 19,220 | 19,220 | - | - | Stock Option (right to buy) | |
| Scott Kellen | CFO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2020 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Randall Michael Giuffre | Director | Grant, award, or other acquisition of securities at price $ 4.59 per share. | 01 Jun 2020 | 7,784 | 93,588 (0%) | 0% | 4.6 | 35,729 | Voting Common Shares, no par value per share |
| Randall Michael Giuffre | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2020 | 13,306 | 13,306 | - | - | Stock Option (right to buy) | |
| Dietrich John Pauls | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2020 | 56,000 | 56,000 | - | - | Stock Option (right to buy) | |
| Sydney A. Gilman | VP, Regulatory Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2020 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Sydney A. Gilman | VP, Regulatory Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2019 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Scott Kellen | CFO and Secretary | Purchase of securities on an exchange or from another person at price $ 2.43 per share. | 19 Aug 2019 | 3,000 | 10,290 (0%) | 0% | 2.4 | 7,290 | Voting Common Shares, no par value per share |
| Harry W. Alcorn | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 2.67 per share. | 16 Aug 2019 | 7,260 | 8,260 (0%) | 0% | 2.7 | 19,365 | Voting Common Shares, no par value per share |
| Richard D. Pilnik | None | Purchase of securities on an exchange or from another person at price $ 2.56 per share. | 16 Aug 2019 | 7,840 | 50,678 (0%) | 0% | 2.6 | 20,039 | Voting Common Shares, no par value per share |
| Dietrich John Pauls | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 2.68 per share. | 16 Aug 2019 | 1,000 | 30,804 (0%) | 0% | 2.7 | 2,677 | Voting Common Shares, no par value per share |
| Harry W. Alcorn | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2019 | 125,000 | 125,000 | - | - | Stock Option (right to buy) | |
| James Parsons | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2019 | 12,950 | 12,950 | - | - | Stock Option (right to buy) | |
| Richard D. Pilnik | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2019 | 18,700 | 18,700 | - | - | Stock Option (right to buy) | |
| Scott Kellen | CFO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2019 | 99,750 | 99,750 | - | - | Stock Option (right to buy) | |
| Todd Verdoorn | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2019 | 71,025 | 71,025 | - | - | Stock Option (right to buy) | |
| Zhenyu Xiao | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2019 | 12,950 | 12,950 | - | - | Stock Option (right to buy) | |
| Randall Michael Giuffre | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2019 | 12,950 | 12,950 | - | - | Stock Option (right to buy) | |
| Dietrich John Pauls | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2019 | 264,000 | 264,000 | - | - | Stock Option (right to buy) | |
| Richard D. Pilnik | None | Purchase of securities on an exchange or from another person at price $ 2.80 per share. | 31 May 2019 | 19,000 | 42,838 (0%) | 0% | 2.8 | 53,200 | Voting Common Shares, no par value per share |
| Scott Kellen | CFO and Secretary | Purchase of securities on an exchange or from another person at price $ 2.94 per share. | 24 May 2019 | 4,000 | 7,290 (0%) | 0% | 2.9 | 11,770 | Voting Common Shares, no par value per share |
| Harry W. Alcorn | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 4.45 per share. | 27 Mar 2019 | 150 | 1,150 (0%) | 0% | 4.5 | 668 | Voting Common Shares, no par value per share |
| Harry W. Alcorn | Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 27 Mar 2019 | 150 | 1,000 (0%) | 0% | 0 | Voting Common Shares, no par value per share | |
| Harry W. Alcorn | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 4.00 per share. | 11 Dec 2018 | 1,000 | 1,000 (0%) | 0% | 4 | 4,000 | Voting Common Shares, no par value per share |
| James Parsons | None | Purchase of securities on an exchange or from another person at price $ 4.00 per share. | 11 Dec 2018 | 2,250 | 6,100 (0%) | 0% | 4 | 9,000 | Voting Common Shares, no par value per share |
| Richard D. Pilnik | None | Purchase of securities on an exchange or from another person at price $ 4.00 per share. | 11 Dec 2018 | 6,250 | 23,838 (0%) | 0% | 4 | 25,000 | Voting Common Shares, no par value per share |
| Scott Kellen | CFO and Secretary | Purchase of securities on an exchange or from another person at price $ 4.00 per share. | 11 Dec 2018 | 1,250 | 3,290 (0%) | 0% | 4 | 5,000 | Voting Common Shares, no par value per share |
| Todd Verdoorn | Chief Scientific Officer | Purchase of securities on an exchange or from another person at price $ 4.00 per share. | 11 Dec 2018 | 1,000 | 2,000 (0%) | 0% | 4 | 4,000 | Voting Common Shares, no par value per share |
| Zhenyu Xiao | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 4.00 per share. | 11 Dec 2018 | 3,250 | 7,100 (0%) | 0% | 4 | 13,000 | Voting Common Shares, no par value per share |
| Randall Michael Giuffre | None | Purchase of securities on an exchange or from another person at price $ 4.00 per share. | 11 Dec 2018 | 11,250 | 85,804 (0%) | 0% | 4 | 45,000 | Voting Common Shares, no par value per share |
| Dietrich John Pauls | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 4.00 per share. | 11 Dec 2018 | 5,000 | 29,804 (0%) | 0% | 4 | 20,000 | Voting Common Shares, no par value per share |